Clinical trial
Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
NCT00385645 · Hospital Clinic of Barcelona, Other · Completed
Key facts
| NCT number | NCT00385645 |
|---|---|
| Title | Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis |
| Official title | Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study |
| Lead sponsor | Hospital Clinic of Barcelona, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Combivir+Kaletra, Combivir+Reyataz |
| Enrollment | 255 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Oct 11, 2006 |
| Last update posted | Mar 31, 2010 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: